Delolimogene mupadenorepvec

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDelolimogene mupadenorepvec
Drug Alias NameDelolimogene mupadenorepvec - Lokon PharmaLOAd-703
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionDendritic cells stimulantsNatural killer cells stimulantsT-cell receptor gene stimulants +[5] 
TargetsT-cell receptorCD40 ligandTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsOvarian NeoplasmsPancreatic NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSweden
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLokon PharmaUppsala University
China Registration ClassN/A

Develop Information

Active CompaniesLokon Pharma AbUppsala University
Inactive CompaniesUppsala University Hospital
Active IndicationsOvarian NeoplasmsPancreatic NeoplasmsColorectal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A